Skip to main content
SpringerLink
Log in

Synthetic Factor Xa Inhibition in Acute Coronary Syndromes

  • Chapter
  • First Online:
Antithrombotic Drug Therapy in Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1219 Accesses

Abstract

Over the last decade, several advances in the management of patients with acute coronary syndrome have been made. Despite these therapeutic advances, the risk of major adverse cardiovascular events related to acute coronary syndrome remains significant. These findings have led to continued efforts to find more efficacious antiplatelet agents and anticoagulants to help reduce the risk of recurrent ischemic events. This chapter reviews the clinical data pertaining to the novel anticoagulant fondaparinux for the treatment of acute coronary syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86.

    Google Scholar 

  2. Boersma E, Harrington RA, Moliterno DJ, White H, Simoons ML (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 360(9329):342–343

    Article  PubMed  Google Scholar 

  3. Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1607–1621

    Article  PubMed  CAS  Google Scholar 

  4. Montalescot G, Barragan P, Wittenberg O et al (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344(25):1895–1903

    Article  PubMed  CAS  Google Scholar 

  5. Peters RJ, Mehta SR, Fox KA et al (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108(14):1682–1687

    Article  PubMed  CAS  Google Scholar 

  6. Stone GW, Grines CL, Cox DA et al (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346(13):957–966

    Article  PubMed  CAS  Google Scholar 

  7. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494–502

    Article  PubMed  CAS  Google Scholar 

  8. (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 12(6 Suppl A):3A–13A.

    Google Scholar 

  9. Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354(14):1477–1488

    Article  PubMed  CAS  Google Scholar 

  10. Cohen M, Demers C, Gurfinkel EP et al (1998) Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 82(5B):19L–24L

    Article  PubMed  CAS  Google Scholar 

  11. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S (2005) Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 112(25):3855–3867

    Article  PubMed  CAS  Google Scholar 

  12. Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77(8):551–556

    Article  PubMed  CAS  Google Scholar 

  13. Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495–1504

    Article  PubMed  CAS  Google Scholar 

  14. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E (2006) Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48(3):438–445

    Article  PubMed  CAS  Google Scholar 

  15. de Lemos JA, Blazing MA, Wiviott SD et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11):1307–1316

    Article  PubMed  Google Scholar 

  16. Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44(3):E1–E211

    Article  PubMed  Google Scholar 

  17. Mehta SR, Cannon CP, Fox KA et al (2005) Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293(23):2908–2917

    Article  PubMed  CAS  Google Scholar 

  18. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47(1):216–235

    Article  PubMed  Google Scholar 

  19. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774–782

    Article  PubMed  Google Scholar 

  20. Moscucci M, Fox KA, Cannon CP et al (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24(20):1815–1823

    Article  PubMed  CAS  Google Scholar 

  21. Rao SV, O’Grady K, Pieper KS et al (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47(4):809–816

    Article  PubMed  Google Scholar 

  22. Rao SV, O’Grady K, Pieper KS et al (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96(9):1200–1206

    Article  PubMed  Google Scholar 

  23. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G (1983) Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116(2):492–499

    Article  PubMed  CAS  Google Scholar 

  24. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW (1997) The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A 94(26):14683–14688

    Article  PubMed  CAS  Google Scholar 

  25. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinay P (1988) Binding of heparin to antithrombin III: a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-d-glucose residue. Carbohydr Res 179:163–172

    Article  PubMed  CAS  Google Scholar 

  26. Petitou M, Lormeau JC, Choay J (1988) Interaction of heparin and antithrombin III. The role of O-sulfate groups. Eur J Biochem 176(3):637–640

    Article  PubMed  CAS  Google Scholar 

  27. Petitou M, Duchaussoy P, Lederman I et al (1987) Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III. Carbohydr Res 167:67–75

    Article  PubMed  CAS  Google Scholar 

  28. Petitou M, Duchaussoy P, Herbert JM et al (2002) The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 28(4):393–402

    Article  PubMed  CAS  Google Scholar 

  29. Donat F, Duret JP, Santoni A et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9

    Article  PubMed  CAS  Google Scholar 

  30. Lieu C, Shi J, Donat F et al (2002) Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 41(Suppl 2):19–26

    Article  PubMed  CAS  Google Scholar 

  31. Simoons ML, Bobbink IW, Boland J et al (2004) A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 43(12):2183–2190

    Article  PubMed  CAS  Google Scholar 

  32. Coussement PK, Bassand JP, Convens C et al (2001) A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 22(18):1716–1724

    Article  PubMed  CAS  Google Scholar 

  33. Mehta SR, Steg PG, Granger CB et al (2005) Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot. Circulation 111(11):1390–1397

    Article  PubMed  CAS  Google Scholar 

  34. Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354(14):1464–1476

    Article  PubMed  CAS  Google Scholar 

  35. Fox KA, Bassand JP, Mehta SR et al (2007) Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 147(5):304–310

    PubMed  Google Scholar 

  36. Mehta SR, Granger CB, Eikelboom JW et al (2007) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50(18):1742–1751

    Article  PubMed  CAS  Google Scholar 

  37. Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295(13):1519–1530

    Article  PubMed  CAS  Google Scholar 

  38. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7):e148–e304

    Article  PubMed  Google Scholar 

  39. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G (2004) A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 22(9):605–620

    Article  PubMed  CAS  Google Scholar 

  40. Sullivan SD, Kwong L, Nutescu E (2006) Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health 9(2):68–76

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado Denver and Health Sciences Center, Aurora, CO, USA

    Michael S. Kim MD & Robert L. Page PharmD

  2. Section of Interventional Cardiology, University of Colorado Denver and Health Sciences Center, Aurora, CO, USA

    Ivan P. Casserly MB, BCh

  3. Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, USA

    Ivan P. Casserly MB, BCh

Authors
  1. Michael S. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Page PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan P. Casserly MB, BCh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan P. Casserly MB, BCh .

Editor information

Editors and Affiliations

  1. Western Reserve Heart Care, Corporate Dr. 1335, Hudson, 44236, U.S.A.

    Arman T. Askari

  2. Dept. Cardiovascular Medicine, Cleveland Clinic, Euclid Ave. 9500, Cleveland, 44195, U.S.A.

    A. Michael Lincoff

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kim, M.S., Page, R.L., Casserly, I.P. (2010). Synthetic Factor Xa Inhibition in Acute Coronary Syndromes. In: Askari, A., Lincoff, A. (eds) Antithrombotic Drug Therapy in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-235-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-235-3_10

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-234-6

  • Online ISBN: 978-1-60327-235-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation